BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, South E, Lowenstein M. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm Reduct J 2021;18:119. [PMID: 34823538 DOI: 10.1186/s12954-021-00572-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Pertl K, Petluri R, Wiest K, Hoffman K, McCarty D, Levander XA, Chan B, Martin SA, Korthuis PT. Recruitment challenges for a prospective telehealth cohort study. Contemp Clin Trials Commun 2023;31:101043. [PMID: 36475092 DOI: 10.1016/j.conctc.2022.101043] [Reference Citation Analysis]
2 Mcdonald R, Bech AB, Clausen T. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: A cross-sectional survey of provider experiences.. [DOI: 10.21203/rs.3.rs-2212348/v1] [Reference Citation Analysis]
3 Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Netw Open 2023;6:e2252381. [PMID: 36692880 DOI: 10.1001/jamanetworkopen.2022.52381] [Reference Citation Analysis]
4 Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, Potenza MN, Ambekar A, Ekhtiari H, Stein D, Khazaal Y, Arunogiri S, Torrens M, Ferri M, Galea-singer S, Baldacchino A. Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. The Lancet Psychiatry 2023;10:50-64. [DOI: 10.1016/s2215-0366(22)00374-1] [Reference Citation Analysis]
5 Galvin E, Desselle S, Gavin B, Quigley E, Flear M, Kilbride K, McNicholas F, Cullinan S, Hayden J. Patient and provider perspectives of the implementation of remote consultations for community-dwelling people with mental health conditions: A systematic mixed studies review. J Psychiatr Res 2022;156:668-78. [PMID: 36399859 DOI: 10.1016/j.jpsychires.2022.10.051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lowenstein M, O’donnell N, Barnes J, Gallagher K, Gehri G, Pomeroy JK, Aronowitz S, Chaiyachati K, Cubbage E, French R, Mcginley S, Salerno B, Perrone J. CareConnect: Adapting a Virtual Urgent Care Model to Provide Buprenorphine Transitional Care. NEJM Catalyst 2022;3. [DOI: 10.1056/cat.22.0274] [Reference Citation Analysis]
7 Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, Garnett I, Lutz R, Mahoney A, Samorano S, Arredondo C, Andres HJ, Coles H, Granillo B. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. PLoS One 2022;17:e0274094. [PMID: 36282806 DOI: 10.1371/journal.pone.0274094] [Reference Citation Analysis]
8 Frost MC, Zhang L, Kim HM, Lin LA. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw Open 2022;5:e2236298. [PMID: 36223118 DOI: 10.1001/jamanetworkopen.2022.36298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 May T, Dawes J, Fancourt D, Burton A. A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives. Int J Drug Policy 2022;106:103752. [PMID: 35653821 DOI: 10.1016/j.drugpo.2022.103752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mahmoud H, Naal H, Whaibeh E, Smith A. Telehealth-Based Delivery of Medication-Assisted Treatment for Opioid Use Disorder: a Critical Review of Recent Developments. Curr Psychiatry Rep 2022. [PMID: 35895282 DOI: 10.1007/s11920-022-01346-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aronowitz SV, Hudgins A. Problematizing "patient stability" in opioid use disorder care: Flexible definitions, (in)flexible treatment. Int J Drug Policy 2022;108:103804. [PMID: 35878509 DOI: 10.1016/j.drugpo.2022.103804] [Reference Citation Analysis]
12 May T, Dawes J, Fancourt D, Burton A. A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives.. [DOI: 10.1101/2022.01.24.22269530] [Reference Citation Analysis]